newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference - BIOAGE LABS INC

  • Financial Performance:

    • Cash runway is just over $350 million, sufficient to fund all milestones discussed including the unannounced peripheral indication and progression of NLRP3 and APJ programs through Phase I.
    • Revenue and profitability figures are not explicitly detailed as the company remains in clinical development stages without marketed products.
  • Guidance and Future Outlook:

    • A Phase I data readout (BE-G102) using the same dosing regimen as the Phase II ophthalmology trial is expected by the end of the current year.
    • An Investigational New Drug (IND) filing for the APJ agonist program is targeted for the end of next year.
    • The company plans to announce a new peripheral indication for its NLRP3 asset next year, selection of which will be informed by data from the QUEL-CV trial.
    • Contingent on positive Phase II results, the company aims to advance directly to a pivotal Phase III trial without intermediate studies.
  • Business Segments and Product Lines:

    • NLRP3 Inhibitor (BE-G102): The lead asset is in Phase II for Diabetic Macular Edema (DME); the trial includes 180 patients across three arms (monotherapy, combination with VEGF, and control) to measure a 4-letter visual acuity improvement in 3 months. It features best-in-class target engagement (98% IL-1β inhibition) and superior blood-retina/blood-brain barrier penetration (Kpuu/CSF of 0.7).
    • APJ Agonist: A novel, orally active molecule distinct from the previously failed Azetaprag (zero structural similarity to mitigate liver toxicity risks); currently preclinical with an IND filing due next year.
    • Ophthalmology Franchise: Focusing initially on DME with future expansion potential into Geographic Atrophy (GA), Uveitis, and MEZI, leveraging the drug's oral administration to address the 30-40% of patients currently untreated due to the invasiveness of eye injections.
    • Partnerships: Preclinical partnership exists with Novartis and Eli Lilly for target identification.
  • Market and Competitive Landscape:

    • Cardiovascular (CV): The cardiovascular indication for NLRP3 is deprioritized following the disappointing Zeus trial results, though the mechanism remains biologically compelling for other indications.
    • Ophthalmology: The market for DME is dominated by injectable therapies (VEGF, IL-6); an oral NLRP3 inhibitor offers a unique value proposition for untreated patients and those refractory to VEGF, potentially sparing injections.
    • Obesity/Metabolic: The APJ space is less crowded than the incretin market; with oral incretins showing variable weight loss, a novel mechanism that preserves muscle mass and complements incretins offers significant differentiation.
  • Risks and Challenges:

    • Cardiovascular Failure: The recent negative data in the Zeus trial for NLRP3 in cardiovascular disease has created investor skepticism and market volatility, necessitating a strategic pivot.
    • Safety Profile: While Phase I data for BE-G102 has been clean, the company acknowledges risks associated with chronic inflammatory inhibition and aims to monitor safety rigorously, particularly regarding infection risks.
    • Trial Endpoints: The Phase II trial is powered for a 4-letter improvement; falling slightly short (e.g., 3 letters) requires careful justification against placebo effects, though 3 letters is considered clinically meaningful for monotherapy in untreated patients.
  • Management Commentary and Tone:

    • Management expressed high confidence in the NLRP3 platform's potential in ophthalmology, emphasizing the unique drug delivery advantages of an oral small molecule over current injectable standards.
    • The tone was strategic and decisive, explicitly stating the deprioritization of the CV indication to focus resources on areas with clearer, shorter-path regulatory endpoints and unmet needs.
    • CEO Kristen Forney highlighted the "fresh start" nature of the APJ program, noting structural improvements to avoid previous liver toxicity issues associated with Azetaprag.
  • Analyst Questions and Answers:

    • Q: Why focus on NLRP3 if the CV target is down? A: Management argued that while the CV outcome was binary and failed, the mechanism targets upstream inflammation with potential for oral delivery in other indications (like DME) where injectables dominate, creating a new market opportunity.
    • Q: Is BE-G102 unique compared to other NLRP3 inhibitors? A: Yes, it boasts the best-in-class brain and eye penetration data (Kpuu 0.7) in the clinic, which is critical for reaching the retina, and superior IL-1β inhibition (98%) compared to competitors' ~90%.
    • Q: What is the strategy for the APJ program? A: To develop an oral APJ agonist that is structurally orthogonal to Azetaprag to ensure safety, with potential for monotherapy (muscle preservation in aging) or combination with incretins for enhanced weight loss.
    • Q: How will the Phase II DME trial be sized and powered? A: 180 patients, 3 arms, 3-month duration, powered for 90% to detect a 4-letter improvement (combination) or 3-letter improvement (monotherapy) vs. VEGF alone.
  • Other Key Points:

    • The QUEL-CV trial data is expected to determine the optimal dosing (30mg, 60mg, or 90mg) for future peripheral indications.
    • Management confirmed that the 30-40% of DME patients currently untreated due to the burden of injections represents the primary addressable market for an oral therapy.
    • The company views the APJ mechanism as a potential "gateway" or maintenance therapy for obesity, particularly for patients intolerant to current incretin therapies.
Company
BIOAGE LABS INC
Keywords
BIOAGE LABS INC